Form 4 for IMNM Immunome Inc.
Accepted 2026-03-31 00:00:00 ET · period of report 2026-03-27 · accession 0001167496-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 2026-03-27 | IMNM | SIEGALL CLAY B | Pres, CEO, Dir | P - Purchase | $19.67 | +25.4K | 690.7K | +4% | +$500.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-27 | P | A | 25,450 | $19.67 | 690,704 | D | — | — | (F1) The weighted average purchase price for the transaction report was $19.67, and the range of prices were between $19.63 and $19.70, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. |